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Gastric cancer remains one of the most serious health problems in
Japan (Moreaux and Bougaran, 1993; Fuch and Mayer, 1995). The
overall increase in life span and the development of new diag-
nostic techniques have led to improved detection of gastric cancer
(Maehara et al, 1995a). One reason for this better outcome is the
predominance of cases of gastric cancer diagnosed at an early
stage (Hisamichi, 1989; Maehara et al, 1993). Mass screening with
double contrast barium study and endoscopy with biopsy have
coincided with an increased recognition of patients with early
gastric cancer, fewer patients with advanced gastric cancer, and a
decrease in the number of cancer deaths (Kaneko et al, 1977;
Noguchi et al, 1989; Hanazaki et al, 1997). Since the 1960s,
radical procedures have been introduced for extensive lymph 
node dissection and the combined resection of adjacent organs
(Korenaga et al, 1988; Maehara et al, 1992, 1996b). In potentially
curable patients with a localized tumour and no evidence of distant
metastasis, extensive en bloc resection led to a substantial increase
in survival time, compared with findings in case of a simple
gastrectomy, a standard procedure in Japan in the 1950s (Kodama
et al, 1981; Korenaga et al, 1988). More radical surgical tech-
niques have been introduced; and anaesthesia, perioperative care,
and nutritional support have all improved (Jentschura et al, 1997).
These changes resulted in improvement in the outcome for
patients over 70 years of age and with gastric cancer (Maehara et
al, 1995a). In Western countries, the rate of early gastric cancer
increased in time trends, but was much lower, compared to related
events in Japan (Sue-Ling et al, 1993; Jentschura et al, 1997). We
find no recent reports on time trends of tumour advance and post-
operative prognosis for subjects with gastric cancer, as based on
analysis of a large number of patients treated in one institution. We
determined time trends of clinicopathologic characteristics and
postoperative prognosis for 2152 patients with gastric cancer
treated with surgical resection between 1965 and 1995, the objec-
tive being to present an overview of the past, present and future of
the surgical treatment for patients with gastric cancer, in Japan.
PATIENTS AND METHODS
Participants and surgical treatment
From 1965 to 1995, 2152 Japanese patients with gastric cancer and
no evidence of any other malignancy underwent gastric resection
in the Department of Surgery II, Kyushu University Hospital,
Fukuoka, Japan. Details of patient data have been meticulously
managed in those periods. The 2152 patients were grouped into
six: group 1 (1965–1970, n = 503); group 2 (1971–1975, n = 350);
group 3 (1976–1980, n = 333); group 4 (1981–1985, n = 325);
group 5 (1986–1990, n = 293); group 6 (1991–1995, n = 348).
Inoperable or non-resected cases (because of advanced stages of
tumours) numbered 130 (20.5%, 130/633) for group 1, 41 (11.7%.
41/391) for group 2, 32 (9.6%, 32/365) for group 3, 43 (13.2%,
43/368) for group 4, 32 (9.8%, 32/325) for group 5 and 25 (6.7%,
25/373) for group 6. From 1975 on, the stomach was resected after
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Table 1 Clinicopathological characteristics in serial cohorts of Japanese patients who underwent surgery for gastric cancer
Factor Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
(n = 503) (n = 350) (n = 333) (n = 325) (n = 293) (n = 348) P value
Age(yrs) 55.3 ± 11.8* 57.5 ± 12.3 59.2 ± 12.3 61.2 ± 12.3 61.5 ± 12.5 62.0 ± 12.1 0.0001
Sex Male 349(69.4) 235 (67.1) 215 (64.6) 222 (68.3) 205 (70.0) 250 (71.8) 0.420
Female 154 (30.6) 115 (32.9) 118 (35.4) 103 (31.7) 88 (30.0) 98 (28.2)
Location of Upper 93 (18.5) 88 (25.1) 68 (20.4) 71 (21.8) 69 (23.5) 88 (25.3) 0.0001
the tumour Middle 138 (27.4) 90 (25.7) 103 (30.9) 85 (26.2) 108 (36.9) 117 (33.6)
Lower 223 (44.3) 143 (40.9) 113 (33.9) 138 (42.5) 99 (33.8) 130 (37.4)
Whole 49 (9.8) 29 (8.3) 49 (14.8) 31 (9.5) 16 (5.5) 13 (3.7)
stomach
Tumour maximal 6.8± 3.6* 7.0± 4.0 7.8± 4.5 6.0± 4.0 4.9± 3.3 4.9± 4.0 0.0001
diameter (cm)
Histology
Well differentiated 230 (46.4) 195 (55.7) 147 (44.5) 153 (47.1) 151 (52.1) 185 (53.3) 0.0148
Poorly differentiated 266 (53.6) 155 (44.3) 183 (55.5) 172 (52.9) 139 (47.9) 162 (46.7)
Others** 7 0 3 0 3 1
Depth of invasion
m 39 (7.7) 41 (11.7) 38 (11.4) 62 (19.1) 82 (28.0) 117 (33.6) 0.0001
sm 50 (9.9) 51 (14.6) 43 (12.9) 60 (18.5) 60 (20.5) 80 (23.0)
mp 50 (9.9) 27 (7.7) 31 (9.3) 22 (6.8) 19 (6.5) 25 (7.2)
ss 63 (12.5) 38 (10.9) 42 (12.6) 18 (5.5) 35 (11.9) 49 (14.1)
se 209 (41.6) 122 (34.9) 111 (33.3) 122 (37.5) 80 (27.3) 66 (19.0)
si 92 (18.3) 71 (20.3) 68 (20.4) 41 (12.6) 17 (5.8) 11 (3.2)
Lymphatic involvement
Negative 35 (32.1) 140 (41.8) 156 (47.4) 182 (56.5) 155 (53.6) 234 (67.2) 0.0001
Positive 74 (67.9) 195 (58.2) 173 (52.6) 140 (43.5) 134 (46.4) 114 (32.8)
Unknown** 394 15 4 3 4 0
Vascular involvement
Negative 47 (78.3) 264 (79.8) 265 (84.1) 265 (82.3) 198 (69.7) 260 (75.1) 0.0002
Positive 13 (21.7) 67 (20.2) 50 (15.9) 57 (17.7) 86 (30.3) 86 (24.9)
Unknown** 443 19 18 3 9 2
Histological lymph
node metastasis
Negative 184 (36.7) 139 (39.8) 134 (40.2) 143 (44.0) 168 (58.3) 218 (63.4) 0.0001
Positive 318 (63.3) 210 (60.2) 199 (59.8) 182 (56.0) 120 (41.7) 126 (36.6)
Unknown** 1 1 0 0 5 4
Peritoneal dissemination
Negative 448 (89.1) 309 (88.3) 290 (87.1) 308 (94.8) 282 (96.2) 337 (96.8) 0.0001
Positive 55 (10.9) 41 (11.7) 43 (12.9) 17 (5.2) 11 (3.8) 11 (3.2)
Liver metastasis
Negative 475 (94.4) 330 (94.3) 316 (94.9) 310 (95.4) 287 (98.0) 340 (97.7) 0.0001
Positive 28 (5.6) 20 (5.7) 17 (5.1) 15 (4.6) 6 (2.0) 8 (2.3)
Stage
Ia 81 (16.1) 80 (22.8) 69 (20.8) 109 (33.5) 130 (45.1) 179 (51.9) 0.0001
Ib 54 (10.7) 37 (10.6) 46 (13.8) 21 (6.5) 31 (10.8) 37 (10.7)
II 70 (13.9) 37 (10.6) 36 (10.8) 43 (13.2) 28 (9.7) 39 (11.3)
IIIa 69 (13.7) 42 (12.0) 42 (12.6) 40 (12.3) 37 (12.8) 36 (10.4)
IIIb 77 (15.4) 50 (14.3) 42 (12.6) 46 (14.2) 27 (9.4) 18 (5.3)
IVa,b 152 (30.2) 104 (29.7) 98 (29.4) 66 (20.3) 35 (12.2) 36 (10.4)
Unknown 0 0 0 0 5 3
Gastric resection
Partial 156 (32.3) 118 (33.7) 144 (43.9) 155 (47.8) 113 (39.0) 144 (41.3) 0.0001
Total 326 (67.7) 232 (66.3) 184 (56.1) 169 (52.2) 177 (61.0) 204 (58.7)
Unknown* 21 0 5 1 3 0
Lymph node dissection
D0 & D1 137 (27.2) 70 (20.0) 93 (27.9) 84 (25.8) 63 (21.5) 37 (10.6) 0.0001
D2 & D3 366 (72.8) 280 (80.0) 240 (74.1) 241 (74.2) 230 (78.5) 311 (89.4)
Operative curability
A 155 (30.9) 132 (37.8) 127 (38.1) 148 (45.5) 172 (59.5) 237 (68.5) 0.0001
B 171 (34.1) 109 (31.2) 98 (29.4) 93 (28.6) 70 (24.2) 66 (19.1)
C 176 (35.1) 108 (30.9) 108 (32.4) 84 (25.8) 47 (16.3) 43 (12.4)
Unkown* 1 1 0 0 4 2
*, mean ± standard deviation
**, Cases excluded from statistical analysis.
m, mucosa; sm, submucosa; mp, muscularis propria; ss, subserosa; se, serosa; si, infiltration into adjacent organsdetermining the resection line at least 3 cm apart from the macro-
scopic edge of the localized tumour and 6 cm for the infiltrative
tumour in case of an advanced tumour, and 2 cm for the localized
tumour and 4 cm for the infiltrative lesion in the early tumour
(Kawasaki et al, 1975). All patients were examined clinically and
pathologically with respect to factors given in Table 1. Pathologic
diagnosis and classification of the resected gastric cancer tissues
were made according to the General Rules for the Gastric Cancer
Study in Surgery and Pathology in Japan (Japanese Gastric Cancer
Association, 1998). The lymph nodes in groups 1, 2 and 3 are
referred to as n1, n2 and n3, respectively, based on the degree of
lymph node metastasis. Lymph node dissection was classified as
follows: D1, complete removal of group 1 lymph nodes alone; D2,
complete removal of group 1 and 2 lymph nodes; and D3,
complete removal of group 1, 2 and 3 lymph nodes. Curability A
means no evidence of residual tumours and with a high probability
of cure, under the following conditions: no serosal invasion; n0
treated by D1, 2, 3 or n1 treated by D2, 3; M0, P0, H0; and the
proximal and distal margins >10 mm. Curability B means no
evidence of residual tumours but not evaluable as ‘Curability A’,
and Curability C means definite residual tumour.
After surgery the patients were entered into a regular follow-up
programs with each or a combination of blood examinations,
roentgenography of the gastrointestinal tract, endoscopic proce-
dures, angiography (from 1970), computed tomography and ultra-
sonography (from 1980). Physical conditions were examined
every 2 weeks in the outpatient department for the first year, and
every 1 to 2 months after 2 years. After 5 years, the cause of death
was obtained from the local physician and always confirmed by a
check of the death certificate.
Statistical methods
The BMDP Statistical Package program (BMDP; Los Angeles,
CA) for the IBM (Armonk, NY) 3090 mainframe computer was
used for all analyses (Dixon, 1988). The BMDP 4F and 3S
programs were used for chi-square and Kruskal-Wallis tests to
compare the data. The BMDP 1L program was used to analyse
survival time by the Kaplan-Meier method and the Mantel-Cox
test was used to test for equality of the survival curves. The BMDP
2L program for simultaneous multivariate adjustment of all
covariates by the Cox regression analysis with forward stepwise
model was used to determine independent factors related to the
prognosis (Cox, 1972). The level of significance was P < 0.05.
RESULTS
Clinicopathologic factors
The clinicopathologic characteristics of patients are given in Table
1. Patients of a more advanced age were seen in recent periods and
the mean age was 7 years older in group 6, compared to that of
group 1. The male to female ratio was about 2:1 for each group.
Tumours in the whole stomach were fewer and those in upper
locations of the stomach increased in recent periods. Tumour size
was smaller, and the peak was noted in case of less than 2 cm, in
group 6 (Figure 1). The well-differentiated tissue type was more
common compared to the poorly differentiated type in recent
periods, and the ratio between well differentiated and poorly
differentiated has been reciprocal in time trends. In recent periods,
depth of invasion was less prominent, in particular, cases of
mucosal and submucosal early gastric cancer significantly
increased, and in group 6, 58.6% of the patients had an early
gastric cancer. The rates of lymphatic invasion and lymph node
metastasis were much lower in recent periods. The rates of
vascular invasion did not decrease in time trends. The rates of peri-
toneal dissemination and liver metastasis were also lower. Thus,
tumours seen in recent periods appear to be less advanced and
detection rates of early stage of gastric cancer have significantly
increased. Stage I was noted in 26.8% of patients for group 1 and
62.5% for group 6.
Surgical treatment
As shown in Table 1, the rate of partial gastrectomy increased
compared to total gastrectomy because of the dominance of early
and small tumours. Extensive lymph node dissection (D2 and D3)
has been routinely carried out in our department over the years and
also in other institutions in Japan. The rate of D2 and D3 was 
as high as 89.3% for group 6. Therefore, curative resection
(curability A and B) was consistently performed throughout.
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Figure 1 Tumour size in successive cohorts of patients with gastric cancer.
Group 1 (1965–1970, n = 503); group 2 (1971–1975, n = 350); group 3
(1976–1980, n = 333); group 4 (1981–1985, n = 325); group 5 (1986–1990, 
n = 293); group 6 (1991–1995, n = 348)Survival rates
Twenty-seven of 2152 patients (1.3%) died within the first 30 post-
operative days; 2.4% (12/503) in group 1; 2.0% (7/350) in group 2;
1.2% (4/333) in group 3; 1.2% (4/325) in group 4; 0% in both
groups 5 and 6. The rate of operative mortality has decreased in
recent periods.
At the time these data were analysed, the median follow-up time
for all 736 survivors was 9.4 years (0.1–32.5 years); 29.0 years
(12.3–32.5) for 63 survivors in group 1; 23.6 years (4.4–26.5) for
70 survivors in group 2; 19.1 years (1.9–21.5) for 73 survivors in
group 3; 13.3 years (0.3–16.5) for 124 survivors in group 4; 8.3
years (0.1–11.5) for 159 survivors in group 5; 4.0 years (0.1–6.8)
for 247 survivors in group 6.
The survival rate of patients with gastric cancer was compared
among the six groups (Figure 2). When gastric cancer deaths and
non-gastric cancer deaths were all included in the survival
analysis, the survival rate improved in recent periods (Figure 2A).
The 5-year survival rate was 44.8% for group 1 and 66.6% for
group 6. When non-gastric cancer deaths were considered as
censored data, the disease-specific survival rate also improved in
recent periods (Figure 2B). The 5-year survival rate was 49.7% for
group 1 and 75.1% for group 6.
Multivariate analysis
To determine which of the covariates listed in Table 1 were perti-
nent prognostic factors of survival time for patients with gastric
cancer, a multivariate analysis with Cox regression analysis with
forward stepwise model was done for 1644 cases and all factors
listed in Table 1 were identified. Ten factors of depth of invasion,
lymph node metastasis, lymph node dissection, tumour size, liver
metastasis, peritoneal dissemination, lymphatic invasion, vascular
invasion, lesion in the whole stomach and lesion in the middle
stomach were all independent prognostic factors (Table 2).
DISCUSSION
This overview covering 31 years revealed that detection of gastric
cancer at an early stage has increased with wide use of diagnostic
procedures of radiography and endoscopy with targeted biopsy
(Hisamichi, 1989). In Japan, mass screening also has a definite
role in diagnosing gastric cancer, in its early stages (Abe et al,
1993). The high curative resectability rate in the screened group
related to a smaller tumour size and to a lower incidence of lymph
node metastasis, liver metastasis and peritoneal dissemination than
in the the non-screened group. In the recent period, 57% of the
tumours was early gastric cancer, in particular 34% was mucosal
gastric cancer, and such screening has contributed to the recent
decline in the number of deaths in subjects with this cancer. The
definition of early gastric cancer was made by the Japanese
Endoscopic Society in 1962 (Yoshimori, 1989), when endoscopic
and radiologic examination were the only diagnostic tools used.
Metastasis to lymph nodes in directly linked to the outcome and
extensive lymph node dissection is a statistically favourable prog-
nostic factor (Maehara et al, 1991). In our study, 89.3% of the
patients were treated with D2 or D3 lymph node disection.
(Maehara et al, 1992). Baba et al (1995) reported that the rate of
recurrence was higher in patients treated with dissection of group 1
lymph nodes than for those with dissection of group 2 or 3 nodes,
in cases of a node-negative early gastric cancer. We noted
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Figure 2 Survival curves of patients undergoing surgery for gastric cancer.
Differences in survival are significant (P = 0.0001) for mortality from gastric
cancer and other diseases (A), and gastric cancer-related deaths only (B),
among six groups. Five-year survival rates for all groups are indicated.
Groups 1–6 were the same as in Figure 1
Table 2 Cox regression analysis of data on patients with gastric cancer
Explanatory variable P value Relative risk
(observed value) (95% confidence interval)
Serosal invasion* 0.0001 2.5479
(negative, positive) (2.0450–3.1747)
Lymph node metastasis 0.0001 3.1736
(negative, positive) (2.4311–4.1432)
Lymph node dissection 0.0001 0.4621
(D0&D1, D2&D3) (0.3709–0.5758)
Tumour size 0.0001 1.0775
(per cm) (1.0534–1.1021)
Liver metastasis 0.0001 3.3877
(negative, positive) (2.6158–4.3869)
Peritoneal dissemination 0.0001 1.6755
(negative, positive) (1.6381–1.7137)
Lymphatic invasion 0.0053 1.3393
(negative, positive) (1.1069–1.6203)
Vascular invasion 0.0069 1.2857
(negative, positive) (0.9849–1.6784)
Location of the tumour 0.0114 1.4039
(not whole stomach, whole stomach) (1.0840–1.8180)
Location of the tumour 0.0391 0.8201
(middle stomach, others) (0.6779–0.9922)
*Serosal invasion negative: m, sm, mp, ss; positive: se, si990 Y Maehara et al
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cytokeratin-positive cancer cells in lymph nodes in 24% of the
patients with node-negative early gastric cancer and who died with
a recurrence (Maehara et al, 1996c). Siewert et al (1996) also
reported that the presence of three or more tumour cells in more
than 10% of the lymph nodes was of significant prognostic value
in the pN0 cases.
Bonenkamp et al (1999) and Cuschieri et al (1999) reported that
D2 patients had a higher operative mortality rate than did D1
patients and that these D2 patients experienced more complica-
tions, thus, D2 provided no survival benefit. Other workers
reported that extensive lymph node dissection did not increase
postoperative mortality rates, but did increase the morbidity rate
(Wu et al, 1995; Robertson et al, 1994). Pacelli et al (1993) and 
de Manzoni et al (1996) found that extended lymphadenectomy
significantly lengthened survival time for patients with gastric
cancer, without increasing operative mortality. A prospective
study done in Germany showed a significant survival advantage of
radical lymphadenectomy for patients with stage II and stage IIIa
disease (Siewert et al, 1993). Thus, there is controversy regarding
the effects of lymph node dissection for gastric cancer (Bunt et al,
1994; Guadagni et al, 1995; McCulloch, 1995; Sakamoto and
Yasue, 1995; Sue-Ling and Johnston, 1995). A number of factors
contribute to the results of these clinical trials; such as surgeon’s
skill and personal attitude towards lymph node dissection, medical
and nursing care, patient’s constitution, the degree of obesity and
multi-organ functions.
Roukos et al (1990) reported that 5.4% of the patients had
metastases in group 2 nodes while group 1 nodes were unaffected.
In these cases, the extent of lymph node metastasis was underesti-
mated by D1 dissection. Therefore, D2 prophylactic lymph node
dissection can make for a curative resection when micrometastases
are present in group 2 lymph nodes. The remaining metastatic
lesions in the lymph nodes may well explain the recurrence in a
variety of organs, including liver and/or peritoneum (Maehara 
et al, 1995b). Preoperative diagnostic rate of lymph node metas-
tasis was 37% in cases of a metastatic lymph node less than 15
mm, determined using helical CT (Fukuya et al, 1995). With
respect to macroscopic findings at the time of operation, the
correct diagnostic rate was only 15% in cases of metastatic lymph
nodes less than 15 mm (Okamura et al, 1988). Thus, preoperative
and macroscopic diagnosis will not precisely predict the presence
of lymph node metastasis, and an exact statistical randomization of
the patients to analyse effects of lymph node dissection against
lymph node metastasis is difficult to carry out, in a prospective
study. Prophylactic lymph node dissection will more likely lead to
a curative procedure with no increase in operative morbidity
(Maehara et al, 1997).
Patients with early gastric cancer with a smaller, macro-
scopically elevated and differentiated tumour can be treated by
endoscopic resection (Sano et al, 1992). Lesions that can be
endoscopically resected comprise elevated mucosal gastric cancer
of less than 2 cm in diameter, and a depressed cancer of less than 
1 cm. Laparoscopic-assisted gastric resection has been done
(Kitano et al, 1995) and lymph node dissection was done safely
using this procedure. Identification of sentinel lymph nodes by
means of vital staining dye and/or lymphoscintingraphy (Alazraki
et al, 1997) may facilitate a less invasive lymphadenectomy,
however the reliability of these approaches for human gastric
cancer should be further investigated.
The postoperative mortality was 2.4% (12/503) and 0% (0/348)
for the earliest and latest period, respectively. Mass screening
provides an excellent opportunity to detect gastric cancer in symp-
tomless subjects (Hanazaki et al, 1997). Thus, the high percentage
of such patients identified at an early stage will reduce mortality
due to gastric cancer. The large decrease in operative mortality is
due to improved surgical techniques but also to improvements in
anaesthesis, metabolic care and intravenous nutrition (Sue-Ling et
al, 1993).
Recurrences are likely to take on a variety of forms and in
different organs, even after curative resection (Maehara et al,
1996b). Distant micrometastasis was detected in patients with
gastric cancer (Schlimok et al, 1991; Maehara et al, 1996ac, 1998),
and a number of factors are involved in these biological behav-
iours of gastric cancer (Maehara et al, 1999). In our institution, an
earlier diagnosis, standardization of surgical techniques, including
routinely performed lymph node dissection, close follow-up
schedules for recurrences and perioperative managements for
patients with gastric cancer have resulted in better survival rates
after gastrectomy, in particular in the later part of the series.
ACKNOWLEDGEMENTS
This work was supported by a Grant-in-Aid for Scientific
Research from the Ministry of Education, Science, Sports and
Culture of Japan.
REFERENCES
Abe S, Lightdale CJ and Brennan MF (1993) The Japanese experience with
endoscopic ultrasonography in the staging of gastric cancer. Gastrointest
Endosc 39: 586–591
Alazraki NP, Eshima D, Eshima LA, Herda SC, Murray DR, Vansant JP and Taylor
AT (1997) Lymphoscintigraphy, the sentinel node concept, and the
intraoperative gamma probe in melanoma, breast cancer and other potential
cancers. Semin Nucl Med 27: 55–67
Baba H, Maehara Y, Takeuchi H, Inutsuka S, Okuyama T, Adachi Y, Akazawa K and
Sugimachi K (1995) Effect of lymph node dissection on the prognosis in
patients with node-negative early gastric cancer. Surgery 117: 165–169
Bonenkamp JJ, Hermans J, Sasako M, van de Velde, CJH and the Dutch Gastric
Cancer Group (1999) Extended lymph-node dissection for gastric cancer. 
N Engl J Med 340: 908–914
Bunt AMG, Hermans J, Boon MC, van de Velde CJH, Sasako M, Fleuren GJ and
Bruijn JA (1994) Evaluation of the extent of lymphadenectomy in a
randomized trial of Western- versus Japanese-type surgery in gastric cancer. 
J Clin Oncol 12: 417–422
Cox DR (1972) Regression models and life tables. J Royal Statist Soc Series B 34:
187–220
Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M,
Fayers P, for the Surgical Co-operative Group (1999) Patient survival after D1
and D2 resections for gastric cancer: long-term results of the MRC randomized
surgical trial. Br J Cancer 79: 1522–1530
de Manzoni G, Verlato G, Guglielmi A, Laterza E, Genna M and Cordiano C (1996)
Prognostic significance of lymph node dissection in gastric cancer. Br J Surg
83: 1604–1607
Dixon WJ (1988) BMDP Statistical Software. Berkeley: University of California
Press
Fuch CS and Mayer RJ (1995) Gastric carcinoma. New Engl J Med 333: 32–41
Fukuya T, Honda H, Hayashi T, Kaneko K, Tateshi Y, Ro T, Maehara Y, Tanaka M,
Tsuneyoshi M, Masuda K (1995) Lymph-node metastases: Efficacy of detection
with helical CT in patients with gastric cancer. Radiology 197: 705–711
Guadagni S, Catarci M and de Manzoni G (1995) D1 versus D2 dissection for
gastric cancer. Lancet 345: 1517
Hanazaki K, Sodeyama H, Wakabayashi M, Miyazaki M, Yokoyama S, Sode Y,
Kawamura N, Miyazaki T and Ohtsuka M (1997) Surgical treatment of gastric
cancer detected by mass screening. Hepato-gastroenterol 44: 1126–1132
Hisamichi S (1989) Screening for gastric cancer. World J Surg 13: 31–7
Japanese Gastric Cancer Association (1998) Japanese classification of gastric
carcinoma -2nd English edition-. Gastric Cancer 1: 10–24Time trends of gastric cancer 991
British Journal of Cancer (2000) 83(8), 986–991 © 2000 Cancer Research Campaign
Jentschura D, Heubner C, Manegold BC, Rumstadt B, Winkler M and Trede M
(1997) Surgery for early gastric cancer: A European one-center experience.
World J Surg 21: 845–849
Kaneko E, Nakamura T, Umeda N, Fujino M and Niwa H (1977) Outcome of gastric
carcinoma detected by gastric mass survey in Japan. Gut 18: 626–630
Kawasaki S (1975) A clinicopathological study on upward intramural extension of
cancer of the stomach. Fukuoka Acta Medica 66: 1–23 (in Japanese with
English Abstract)
Kitano S, Shimoda K, Miyahara M, Shiraishi N, Bandoh T, Yoshida T, Shuto K and
Kobayashi M (1995) Laparoscopic approaches in the management of patients
with early gastric carcinomas. Surg Laparosc Endosc 5: 359–362
Kodama Y, Sugimachi K, Soejima K, Matsusaka T and Inokuchi K (1981)
Evaluation of extensive lymph node dissection for carcinoma of the stomach.
World J Surg 5: 241–248
Korenaga D, Okamura T, Baba H, Saito A and Sugimachi K (1988) Results of
resection of gastric cancer extending to adjacent organs. Br J Surg 75: 12–15
Maehara Y, Moriguchi S, Kakeji Y, Orita H, Haraguchi M, Korenaga D and
Sugimachi K (1991) Prognostic factors in adenocarcinoma in the upper one-
third of the stomach. Surg Gynecol Obstet 173: 223–226
Maehara Y, Okuyama T, Moriguchi S, Orita H, Kusumoto H, Korenaga D and
Sugimachi K (1992) Prophylactic lymph node dissection in patients with
advanced gastric cancer promotes increased survival time. Cancer 70:
392–395
Maehara Y, Okuyama T, Oshiro T, Baba H, Anai H, Akazawa K and Sugimachi K
(1993) Early carcinoma of the stomach. Surg Gynecol Obstet 177: 593–597
Maehara Y, Oshiro T, Oiwa H, Oda S, Baba H, Akazawa K and Sugimachi K
(1995a) Gastric cancer in patients over 70 years of age. Br J Surg 82: 102–105
Maehara Y, Oshiro T, Baba H, Ohno S, Kohnoe S and Sugimachi K (1995b)
Lymphatic invasion and potential for tumor growth and metastasis in patients
with gastric cancer Surgery 117: 380–385
Maehara Y, Yamamoto M, Oda S, Baba H, Kusumoto T, Ohno S, Ichiyoshi Y and
Sugimachi K (1996a) Cytokeratin-positive cells in bone marrow for identifying
distant micrometastasis of gastric cancer. Br J Cancer 73: 83–87
Maehara Y, Emi Y, Baba H, Adachi Y, Akazawa K, Ichiyoshi Y and Sugimachi K
(1996b) Recurrences and related characteristics of gastric cancer. Br J Cancer
74: 975–979
Maehara Y, Oshiro T, Endo K, Baba H, Oda S, Ichiyoshi Y, Kohnoe S and
Sugimachi K (1996c) Clinical significance of occult micrometastasis in lymph
nodes from patients with early gastric cancer who died of recurrence. Surgery
119: 397–402
Maehara Y, Tomoda M, Tomisaki S, Ohmori M, Baba H, Akazawa K and Sugimachi
K (1997) Surgical treatment and outcome for node-negative gastric cancer.
Surgery 121: 633–639
Maehara Y, Hasuda S, Abe T, Oki E, Kakeji Y, Ohno S and Sugimachi K (1998)
Tumor angiogenesis and micrometastasis in bone marrow of patients with early
gastric cancer. Clin Cancer Res 4: 2129–2134
Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, Baba H,
Kohnoe S and Sugimachi K (1999) Role of transforming growth factor-β 1 in
invasion and metastasis in gastric carcinoma. J Clin Oncol 17: 607–614
McCulloch P (1995) D1 versus D2 dissection for gastric cancer. Lancet 345:
1516–1517
Moreaux J and Bougaran J (1993) Early gastric cancer. A 25-year surgical
experience. Ann Surg 217: 347–355
Noguchi Y, Imada T, Matsumoto A, Coit DG and Brennan MF (1989) Radical
surgery for gastric cancer. A review of the Japanese experience. Cancer 64:
2053–2062
Okamura T, Tsujitani S, Korenaga D, Haraguchi M, Baba H, Hiramoto Y and
Sugimachi K (1988) Lymphadenectomy for cure in patients with early gastric
cancer and lymph node metastasis. Am J Surg 155: 476–480
Pacelli F, Doglietto GB, Bellantone R, Alfieri S, Sgadari A and Crucitti F (1993)
Extensive versus limited lymph node dissection for gastric cancer: a
comparative study of 320 patients. Br J Surg 80: 1153–1156
Robertson CS, Chung SCS, Woods SDS, Griffin SM, Raimes SA, Lau JTF and Li
AKC (1994) A prospective randomized trial comparing R1 subtotal gastrectomy
with R3 total gastrectomy for antral cancer. Ann Surg 220: 176–182
Roukos DH, Hottenrott C, Lorenz M and Koutsogiorgas-Couchell S (1990) 
A critical evaluation of effectivity of extended lymphadenectomy in patients
with carcinoma of the stomach. J Cancer Res Clin Oncol 116: 307–313
Sakamoto J and Yasue M (1995) Extensive lymphadenectomy for gastric cancer
patients: what can the results of one trial tell us? Lancet 345: 742–743
Sano T, Kobori O and Muto T (1992) Lymph node metastasis from early gastric
cancer: endoscopic resection of tumour. Br J Surg 79: 241–244
Schlimok G, Funke I, Pantel K, Strobel F, Lindemann F, Witte J and Riethmüller G
(1991) Micrometastatic tumour cells in bone marrow of patients with gastric
cancer: Methodological aspects of detection and prognostic significance. Eur J
Cancer 27: 1461–1465
Siewert JR, Böttcher K, Roder JD, Busch R, Hermanek P, Meyer HJ and the German
Gastric Carcinoma Study Group (1993) Prognostic relevance of systematic
lymph node dissection in gastric carcinoma. Br J Surg 80: 1015–1018
Siewert JR, Kestlmeier R, Busch R, Böttcher K, Roder JD, Müller J, Fellbaum C and
Höfler H (1996) Benefits of D2 lymph node dissection for patients with gastric
cancer and pN0 and pN1 lymph node metastases. Br J Surg 83: 1144–1147
Sue-Ling HM and Johnston D (1995) D1 versus D2 dissection for gastric cancer.
Lancet 345: 1515–1516
Sue-Ling HM, Johnston D, Martin IG, Dixon MF, Lansdown MRJ, McMahon MJ
and Axon ATR (1993) Gastric cancer: a curable disease in Britain. Gut 307:
591–596
Wu C-W, Hsieh M-C, Lo S-S, Wang L-S, Hsu W-H, Lui W-Y, Huang M-H and
P’eng F-K (1995) Morbidity and mortality after radical gastrectomy for
patients with carcinoma of the stomach. J Am Coll Surg 181: 26–32
Yoshimori M (1989) The natural history of early gastric cancer. Jpn J Clin Oncol 19:
89–93